Chronic Hepatitis Clinical Trial
Official title:
The Impact of Hepatic Steatosis on Chronic Hepatitis B Virus Infection
This study aims to evaluate the prevalence and severity of hepatic steatosis in CHB and investigate the relationship between hepatic steatosis and viral load, liver biochemistry, liver fibrosis, and inflammation in CHB
This hospital-based cohort study will be conducted on 80 adult hepatitis B surface antigen (HBsAg) carriers presented to the Tropical Medicine and Gastroenterology outpatient clinic, at Sohag University Hospital Exclusion criteria Patients with serological evidence of HCV. HBV patients who had received or are currently under anti-viral therapy. Alcohol consumption. Decompensated liver disease. Patients with HCC. Patients are known to have another chronic liver disease (e.g. autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease, Haemochromatosis, or drug-induced chronic hepatitis). Patients with contraindications to liver biopsy such as uncooperative patients, prothrombin time (PT) >4 seconds more than control, INR greater than 1.6, platelets count <100.000/mm3After taking informed written consent, the participants will be subjected to: Clinical evaluation: medical history and physical examination. Laboratory investigations: Complete blood count. Prothrombin time and concentration. Liver function tests Anti-HCV. HBeAg. HBV DNA. Abdominal ultrasonography Ultrasound-guided percutaneous liver biopsy ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01833611 -
Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT
|
Phase 4 | |
Completed |
NCT00771446 -
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03731923 -
Abbreviated MRI for HCC Surveillance
|
N/A | |
Recruiting |
NCT03013556 -
Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
|
Phase 4 | |
Recruiting |
NCT05181826 -
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
|
||
Active, not recruiting |
NCT02143180 -
Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study
|
N/A | |
Completed |
NCT00596414 -
Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial
|
Phase 4 | |
Active, not recruiting |
NCT02772003 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 | |
Terminated |
NCT04775797 -
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
|
Phase 1 | |
Terminated |
NCT03487848 -
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
|
Phase 2 | |
Recruiting |
NCT02822079 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 | |
Recruiting |
NCT04446832 -
VACcination of LIver Transplantation Candidates
|
||
Completed |
NCT01121705 -
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
|
Phase 3 | |
Completed |
NCT02742597 -
Patient-Centred Innovations for Persons With Multimorbidity - Ontario
|
N/A | |
Not yet recruiting |
NCT05062967 -
Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
|
||
Completed |
NCT01380938 -
Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)
|
Phase 3 | |
Recruiting |
NCT01413360 -
The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
|
Phase 4 | |
Terminated |
NCT00496158 -
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
|
Phase 3 | |
Terminated |
NCT00496002 -
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
|
Phase 3 | |
Completed |
NCT02789800 -
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
|
N/A |